Markers of inflammation such as highsensitivity C-reactive protein (CRP) were shown to be elevated in patients with hypertension. Small trials using statin therapy showed blood-pressure (BP) reductions, but it is unknown whether this association extends to larger populations. The objective of this study was to determine whether statin use was associated with better blood-pressure control in adults with hypertension and whether inflammation levels mediated this relationship.
C
hronic low-grade inflammation was shown to play an integral role in the pathogenesis of vascular disease and may also be implicated in the development of hypertension, either as a primary or secondary event. 1 Indeed, clinical studies demonstrated increased levels of well-recognized inflammatory markers such as high-sensitivity C-reactive protein (hsCRP) in patients with hypertension, even after adjustment for potential confounding factors. 2 Furthermore, elevated hsCRP levels were also documented in individuals with prehypertension. 3 Further evidence demonstrates that drugs commonly used in the management of hyperlipidemia, such as 3-hydroxy-3 methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), have anti-inflammatory properties and may also reduce blood pressure. 4 Kanbay et al investigated the impact of atorvastatin 20 mg/day on 49 hypertensive dyslipidemic patients (32 on statin and 17 controls on diet alone) and found reductions in systolic (Ϫ5.7 mm Hg) and diastolic (Ϫ4.2 mm Hg) blood pressure after 8 weeks. 5 Magen et al 6 produced similar findings using atorvastatin 20 mg/day for 8 weeks in 48 resistant hypertensive patients; there were significant reductions in systolic (Ϫ13.7 Ϯ 5.6 mm Hg, P Ͻ .001) and diastolic (Ϫ7.8 Ϯ 5.7 mm Hg, P Ͻ .01) blood pressure.
This study examined the relationship between blood pressure and statin use in individuals with hypertension. We conducted our investigation in a nationally representative sample of noninstitutionalized Americans (National Health and Nutrition Examination Survey [NHANES]).
Our objective was to determine whether statin use is associated with blood-pressure levels Ͻ140/90 mm Hg in adults with hypertension without a history of cardiovascular disease and whether C-reactive protein (CRP) levels modify the association.
Methods
This study analyzed data in the public-use dataset of the most recent NHANES. We derived the study sample from participants in the NHANES 1999 -2002 (NHANES 99 -02), a recent version of this nationally representative, complex, multistage, probability-based survey of the civilian, noninstitutionalized population of the US. Detailed information about the survey design, questionnaires, laboratory analyses, and examination methodology can be found on the Web site for the Centers for Disease Control, National Center of Health Statistics (http://www.cdc.gov/nchs/ nhanes.htm). From a total population of 21,004 individuals, 6671 were adults aged Ն40 years. Of these, 2584 had a history of hypertension or had blood pressure Ն140/90 mm Hg and did not have a previous history of cardiovascular disease (CVD). The Institutional Review Board at the Medical University of South Carolina (Charleston, SC) reviewed this research, and it is exempt from further review.
C-reactive protein was measured as part of the NHANES 99 -02 physical and laboratory examination using highly sensitive techniques. Standard phlebotomy methods were used to obtain specimens. The threshold for elevated CRP was defined by American Heart Association guidelines, which designate CRP levels Ն3.0 mg/L as being associated with high cardiovascular risk. 7 Demographic variables (age, race, and sex) were included as control variables because of their known impact on blood pressure. We controlled for body mass index (BMI; kg/ m 2 ) because of its link to blood pressure and its known association with CRP. We also controlled for a history of diabetes, current smoking status, exercise, low-salt diets to reduce blood pressure, and any antihypertensive medications, all of which are included in the history information obtained from each NHANES participant. Statin use was ascertained in the medication file of the NHANES, where the complete list of medications taken by each participant is detailed. The standard generic ingredient code names for statins included: atorvastatin calcium, cerivastatin sodium, fluvastatin sodium, lovastatin, pravastatin sodium, and simvastatin. No attempt was made to differentiate between statin type.
Because of the complex sampling design, appropriate weighting factors (based on statistical stratification and population estimates) were taken into account when calculating population-based frequency estimates. We used SUDAAN (Research Triangle Institute, Research Triangle, NC), a specialized statistical program that accounts for the complex weighting of the NHANES 99 -02 sample. The use of SUDAAN allowed us to correct for unequal probabilities of selection and different response rates, ensuring that the results could be generalized to the noninstitutionalized civilian population of the US. Thus, the percentages and odds ratios in this study represent weighted values. In addition, SUDAAN adjusts standard errors to account for the weighting, stratification, and clustering of the complex sampling design to ensure that expressed P values are valid. Descriptive statistics for the two comparison groups (statin and no statin) were performed to illustrate the demographic characteristics of the study population. We calculated the percentage of each group who had their blood pressure under control, defined as systolic blood pressure Ͻ140 mm Hg and diastolic blood pressure Ͻ90 mm Hg. Logistic regression modeling was used to predict the effect of statin use on bloodpressure control. Model 1 included age, race, and sex; Model 2 added BMI and diabetes; and Model 3 further added the covariates smoking, exercise, a low-salt diet, and use of antihypertensive medication. We also tested the interaction between created models by replacing the two variables of statin use and antihypertensive use with a single interaction variable. Model 4 was created using Model 3 with the addition of CRP as a control variable to determine whether it affected the relationship between statin use and blood-pressure control. Because CRP has a skewed distribution, we used the natural log transformation of CRP. Standardized betas and P values were obtained from the multivariate analysis output. Model 5 was created to further control for cholesterol level. In addition, models were stratified according to whether participants used antihypertensive medication. Statistical significance was defined as P Յ .05 without correction for multiple comparisons, because the specific analyses were hypothesized and planned in advance.
Results
Among US adults aged Ն40 years with a history of hypertension and no history of CVD, 14.2% were using statin medications. There were no significant distributions in the percentage of the population using statins based on age, sex, BMI, or exercise status (Table 1) . Whites were significantly more likely to be using statin medications than African Americans, and patients with diabetes were more likely to be using statin medications than nondiabetic subjects. Compared with people not using a statin medication, significantly more statin users had blood pressure Ͻ140/90 mm Hg (52.2% v 38.0%), were nonsmokers (85.0% v 79.8%), were using antihypertensive medication (74.9% v 50.1%), were on a low-salt diet (53.2% v 38.2%), or had total cholesterol levels Յ200 mg/dL (50.4% v 35.6%). The median CRP among statin users (2.37 mg/L; 95% confidence interval [CI], 1.97 to 2.74) was significantly lower than among nonusers (3.02 mg/L; 95% CI, 2.80 to 3.31).
After controlling for age, race, and sex (Model 1), statin users were two times (95% CI, 1.46 to 2.72) more likely to have their blood pressure Ͻ140/90 mm Hg than nonusers of statin medications (Table 2 ). This likelihood remained unchanged when adding BMI and diabetes to the model (Model 2). The likelihood of having blood pressure Ͻ140/90 mm Hg was still 46% more likely among statin users compared with nonusers (95% CI, 1.05 to 2.05) after adding smoking, exercise, low-salt diet, and antihypertensive medications to the model (Model 3). Adding CRP to the model, either as the log-transformed (Table 2) or categorical variable (odds ratio, 1.43; 95% CI, 1.02 to 2.02), had virtually no effect on the calculated likelihood of having blood pressure under control (Model 4). Adding cholesterol as a control variable resulted in statins no longer being significantly associated with blood pressure Ͻ140/90 mm Hg (Model 5). Further models were constructed, stratified according to use of antihypertensive medication. In these analyses, shown in the last two columns of Table 2 , the association between statin use and blood pressure is present in participants who use antihypertensive medication but is not present among those who do not use such medications.
Discussion
The findings of this study from a nationally representative sample of noninstitutionalized adults indicate that the use of a statin is associated with a BP level Ͻ140/90 mm Hg in people with hypertension and no history of previous CVD. The relationship was maintained after controlling for factors that could confound the association, including age, race, sex, BMI, diabetes, smoking, exercise, a lowsalt diet, and use of antihypertensive medication. After the addition of CRP to the model, the relationship between statin use and blood pressure was still present to essentially the same degree, which indicates that the relation- ship may be independent of statins' anti-inflammatory effects.
The finding of better blood-pressure control in individuals from a nationally representative sample of people using statins adds to the emerging evidence from small clinical trials regarding the impact of statins on blood pressure. 8 Borghi et al 9 followed 1356 people for 5 years in their investigation of different cholesterol-lowering strategies in the Brisighella Heart Study and found that the use of statins was significantly related to lower blood pressure at follow-up. Glorioso et al 10 examined the effect of pravastatin and placebo in 30 patients with hypertension and dyslipidemia over 32 weeks, and found that pravastatin decreased systolic and diastolic blood pressure (Ϫ8 and Ϫ5 mm Hg, respectively, both P ϭ .001). However, not all clinical studies have demonstrated a blood pressure-lowering effect from statins. Two studies using simvastatin for 8 to 16 weeks showed no impact on blood pressure. 11, 12 Another study found no effect from 10 to 80 mg of lovastatin daily for 6 months in 213 patients with hypertension. 13 In a more recent study of 85 individuals with hypertension and hyperlipidemia, no reduction in blood pressure was demonstrated after 12 months among participants who were randomized to receive pravastatin, fluvastatin, simvastatin, or a nonstatin drug. 14 The finding in the current study of better blood-pressure control in individuals receiving statins is consistent with the hypothesis that statins may have an antihypertensive effect. 8 Mechanistically, the use of statins may be linked to hypertension through inflammation, endothelial dysfunction, or arterial stiffness. 15 The finding in the current study that the use of statins was related to blood pressure Ͻ140/90 mm Hg only when also using antihypertensive medication may be due to some physiologic effects, may be a marker of improved adherence with medications, or may be due to other causes. As for possible physiologic effects, the recent review by Endres 16 emphasized the "pleiotropic" effects of statins, including improved endothelial function, increased nitric oxide bioavailability, antioxidant properties, stabilization of atherosclerotic plaques, and anti-inflammatory effects. In the current study, the association between statin use and lower blood pressure remained unchanged after controlling for CRP level. Thus, the relationship of statin use and blood pressure may not be due to inflammation but to other mechanisms such as effects on the renin-angiotensin system or endothelial vasoreactivity. 8 Another possibility is that CRP may not be an accurate measure of the anti-inflammatory activity of statins, although CRP is considered the best available measure of vascular inflammation. 17 The limitations of the current study include the possibility of uncontrolled or unknown factors that could confound the association between statin use and blood pressure. However, we accounted for the most likely demographic and cardiovascular risk factors. This study was also limited by the lack of availability of other measures of endothelial function and oxidative stress in the NHANES database. In addition, misclassification bias also is possible, due to the use of self-reported data for medication use, exercise, and diet information. Individuals may have only just begun taking a statin and were likely taking statins for varying amounts of time. Finally, because of the cross-sectional nature of the data, no definitive statement can be made regarding cause and effect.
The strengths of the study include the large and nationally representative sample size and the ability to control for a variety of possible confounding factors. The consistent direction and strength of the association after controlling for demographic, lifestyle, and cardiovascular risk factors support the verity of the findings. The results of the current study, taken together with the findings of previous prospective studies on statin use and blood pressure, support the conclusion that statin use is associated with blood pressure Ͻ140/90 mm Hg. The confirmation of the association in a large, diverse population, and its persistence after controlling for age, race, sex, BMI, diabetes, smoking, exercise, and low-salt diet, strengthens the evidence for the relationship between statin use and blood pressure. The association was most evident among participants who used antihypertensive medications as well as statins. Future research could further characterize the impact of statin use on blood pressure, to further elucidate the possible mechanisms for the effect of statins, and to ascertain their clinical role in blood-pressure management.
